UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 99

Sortiert nach

376 Radiation sub-study to characterize safety and tolerability of low-dose radiation in combination with afami-cel in patients with advanced cancers (NCT03132922)

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A407-A407

2021

Volltextzugriff (PDF)

Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma

Clinical cancer research, 2020-11, Vol.26 (22), p.5869-5878

2020

Volltextzugriff (PDF)

Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma

Journal of clinical oncology, 2022-06, Vol.40 (17), p.1939-1948

2022

Volltextzugriff (PDF)

Identity-Trajectories of Early Career Researchers: Unpacking the Post-PhD Experience

Lynn McAlpine, Cheryl Amundsen

1, 2017

Volltextzugriff (PDF)

Measurement properties of the neck disability index: a systematic review

The journal of orthopaedic and sports physical therapy, 2009-05, Vol.39 (5), p.400-C12

2009

Volltextzugriff (PDF)

Autologous T cell therapy for MAGE-A4 + solid cancers in HLA-A02 + patients: a phase 1 trial

Nature medicine, 2023-01, Vol.29 (1), p.104-114

2023

Volltextzugriff (PDF)

Post-PhD Career Trajectories: Intentions, Decision-Making and Life Aspirations

Lynn McAlpine, Cheryl Amundsen

1, 2016

Volltextzugriff (PDF)

Abstract 4554: Functionally distinct T cell subsets contribute to ImmTAC-mediated anti-tumor response

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4554-4554

2020

Volltextzugriff (PDF)

The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e14531-e14531

2023

Volltextzugriff (PDF)

The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.11563-11563

2023

Volltextzugriff (PDF)

Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9523-9523

2019

Volltextzugriff (PDF)

A TCR/anti-CD3 bispecific fusion protein targeting gp100 potently activated anti-tumor immune responses in metastatic melanoma

Clinical cancer research, 2020-08, Vol.26 (22), p.5869-5878

2020

Volltextzugriff (PDF)

Abstract 3655: Biomarker strategy to guide the clinical development of ImmTACTM molecules, a novel class of bispecific T cell engaging biologic drugs

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3655-3655

2017

Volltextzugriff (PDF)

Abstract 892: Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4) demonstrates durable clinical responses by inducing broad immune engagement with anti-tumor activity

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.892-892

2023

Volltextzugriff (PDF)

Abstract A023: Identifying new therapeutic indications for afamitresgene autoleucel (“afami-cel” [formerly ADP-A2M4]) in adult and pediatric sarcomas using MAGE-A4 immunohistochemistry

Clinical cancer research, 2022-09, Vol.28 (18_Supplement), p.A023-A023

2022

Volltextzugriff (PDF)

Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.9531-9531

2017

Volltextzugriff (PDF)

373 Enhancement of TCR-engineered T-cells targeting MAGE-A4 antigen by co-expression of CD8α and inhibition of AKT signaling during ex vivo T-cell expansion

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A401-A401

2021

Volltextzugriff (PDF)

Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients

Molecular therapy. Methods & clinical development, 2024-06, Vol.32 (2), p.101265, Article 101265

2024

Volltextzugriff (PDF)

Abstract LB001: Identifying MAGE-A4-positive tumors for SPEAR T-cell therapies in HLA-A02-eligible patients

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.LB001-LB001

2022

Volltextzugriff (PDF)

Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3016-3016

2016

Volltextzugriff (PDF)

Abstract A35: Biomarker Strategy To Guide Clinical Development Of ImmTAC™ molecules , A Novel Class Of Bispecific T Cell Engaging Biologic Drugs

Cancer immunology research, 2017-03, Vol.5 (3_Supplement), p.A35-A35

2017

Volltextzugriff (PDF)

G-protein-coupled receptor heterodimerization: assay technologies to clinical significance

Current opinion in drug discovery & development, 2007-09, Vol.10 (5), p.580

2007

Volltextzugriff (PDF)

An analysis of the New Criticism and reader response theories of criticism with implications for teaching literature in the secondary schools

McAlpine, Cheryl Gwen

1995

Volltextzugriff (PDF)

Identity-trajectory: Reframing early career academic experience

British educational research journal, 2014-12, Vol.40 (6), p.952-969

2014

Volltextzugriff (PDF)

Challenging the taken-for-granted: how research analysis might inform pedagogical practices and institutional policies related to doctoral education

Studies in higher education (Dorchester-on-Thames), 2012-09, Vol.37 (6), p.683-694

2012

Volltextzugriff (PDF)

1 – 25 von 99

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(93)

Publikationsform

Sprache

Englisch
(99)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Social Sciences
(24)
Education & Educational Research
(21)
Higher & Further Education, Tertiary Education
(20)
Adult Education, Continuous Learning
(13)
Education
(12)
Higher Education
(11)
Doctoral Student
(9)
Humans
(9)
Graduate Students
(8)
Life Sciences & Biomedicine
(8)
Science & Technology
(8)
Organization & Management Of Education
(7)
Sociology
(7)
Doctoral Degrees
(6)
Longitudinal Studies
(6)
Research-Teaching Position
(6)
Agency
(5)
Career Development
(5)
Doctoral Education
(5)
Academic Work
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

376 Radiation sub-study to characterize safety and tolerability of low-dose radiation in combination with afami-cel in patients with advanced cancers (NCT03132922)

Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma

Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma

Identity-Trajectories of Early Career Researchers: Unpacking the Post-PhD Experience

Measurement properties of the neck disability index: a systematic review

Autologous T cell therapy for MAGE-A4 + solid cancers in HLA-A02 + patients: a phase 1 trial

Post-PhD Career Trajectories: Intentions, Decision-Making and Life Aspirations

Abstract 4554: Functionally distinct T cell subsets contribute to ImmTAC-mediated anti-tumor response

The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma

The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma

Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma

A TCR/anti-CD3 bispecific fusion protein targeting gp100 potently activated anti-tumor immune responses in metastatic melanoma

Abstract 3655: Biomarker strategy to guide the clinical development of ImmTACTM molecules, a novel class of bispecific T cell engaging biologic drugs

Abstract 892: Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4) demonstrates durable clinical responses by inducing broad immune engagement with anti-tumor activity

Abstract A023: Identifying new therapeutic indications for afamitresgene autoleucel (“afami-cel” [formerly ADP-A2M4]) in adult and pediatric sarcomas using MAGE-A4 immunohistochemistry

Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma

373 Enhancement of TCR-engineered T-cells targeting MAGE-A4 antigen by co-expression of CD8α and inhibition of AKT signaling during ex vivo T-cell expansion

Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients

Abstract LB001: Identifying MAGE-A4-positive tumors for SPEAR T-cell therapies in HLA-A02-eligible patients

Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma

Abstract A35: Biomarker Strategy To Guide Clinical Development Of ImmTAC™ molecules , A Novel Class Of Bispecific T Cell Engaging Biologic Drugs

G-protein-coupled receptor heterodimerization: assay technologies to clinical significance

An analysis of the New Criticism and reader response theories of criticism with implications for teaching literature in the secondary schools

Identity-trajectory: Reframing early career academic experience

Challenging the taken-for-granted: how research analysis might inform pedagogical practices and institutional policies related to doctoral education

Suchergebnisse filtern